New Stock Listings - The new stock "同宇新材" (code: 301630) is listed at an issue price of 84 on July 10, 2025[1] - "中程退" (code: 300208) and "退市锦港" (code: 600190) have 6 trading days remaining until their last trading day[1] - "恒立退" (code: 000622) has 3 trading days remaining until its last trading day[1] Delisting and Trading Alerts - "退市九有" (code: 600462) has 2 trading days remaining until its last trading day[1] - "工智退" (code: 000584) will have its last trading day on July 10, 2025[1] - "美迪西" (code: 688202) is listed with no specific trading alerts mentioned[1] Market Volatility - "北方长龙" (code: 301357) has been flagged for severe abnormal fluctuations[1] - "浙江东日" (code: 600113) and "诺德股份" (code: 600110) have also been noted for abnormal trading activities[1] - "长春一东" (code: 600148) is included in the list of stocks with trading alerts[1]

New Stock Listings - Yitang Co., Ltd. (688729) listed at an issue price of 8.45 on July 8, 2025[1] - Jichuan Pharmaceutical (600566) has a tender offer period from June 18 to July 17, 2025[1] - ST Yazhen (603389) has a tender offer period from June 10 to July 9, 2025[1] Delisting and Trading Reminders - Tui Shi Jin Gang (600190) has 8 trading days remaining until the last trading day[1] - Hengli Tui (000622) has 5 trading days remaining until the last trading day[1] - Tui Shi Jiu You (600462) has 4 trading days remaining until the last trading day[1] Market Volatility - North China Long Dragon (301357) reported severe abnormal fluctuations[1] - Multiple stocks including ST Zhengping (603843) and Hunan Tianyan (600698) have reported abnormal fluctuations[3]

Market Overview - On July 8, A-shares opened mixed, with the Shanghai Composite Index up by 0.04%, while the Shenzhen Component and ChiNext indices were in the red. However, by the time of reporting, all three indices turned positive, with the ChiNext index rising over 1% [1][2]. Sector Performance - The morning session saw gains in sectors such as electronics, building materials, telecommunications, and computers, with PCB, CRO, and consumer electronics outsourcing stocks performing well. Conversely, public utilities and banking sectors showed weakness [2][3]. PCB Sector - PCB concept stocks continued to strengthen, with International Composite Materials and Yidong Electronics hitting the 20% daily limit up. Jin'an Guoji achieved a four-day consecutive rise, while Honghe Technology had four limit-up days in six days [8][9]. Pharmaceutical Sector - The pharmaceutical sector was notably strong, with CRO, innovative drugs, and weight-loss drug stocks collectively rising. Lianhuan Pharmaceutical achieved a consecutive limit-up, while companies like Weixin Kang, Hasan Lian, and Xiaofang Pharmaceutical also hit the limit-up. Toxin Pharmaceutical and Ruizhi Pharmaceutical saw increases exceeding 10% [4][5][6]. Notable Stock Movements - Fujilai (301258) surged to a limit-up of 20.01%, reaching a price of 39.28 CNY per share shortly after opening. Other notable stocks included Tuoxin Pharmaceutical and Ruizhi Pharmaceutical, which rose by 13.27% and 12.88%, respectively [5][6]. Regulatory Issues - Ruiskanda faced a trading halt due to a 9.95% drop, attributed to regulatory issues involving its chairman and director, who are under criminal coercive measures for alleged violations related to information disclosure. The company had previously faced administrative penalties from the CSRC [11][13].

【导读】医药股盘初拉升， PCB 概念股持续火热 中国基金报记者 晨曦 大家好！来一起关注最新的市场行情和资讯 ~ 7 月 8 日， A 股三大指数开盘涨跌不一，上证指数高开 0.04% ，深证成指、创业板指飘 绿。盘初市场拉升上行，截至发稿，三大指数集体飘红，创业板指涨超 1% 。 | 3480.61 | ﻳ | 10510.71 | [ | 2154.84 | | --- | --- | --- | --- | --- | | 上证指数 +0.22% | | 深证成指 +0.72% | | 创业板指 +1.16% | 盘面上，上午电子、建材、通信、计算机等板块涨幅居前，电路板、 CRO 、消费电子代工等 概念股走高；公用事业、银行等板块不振。 | Wind热门概念指数 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | CRO | 炒股软件 | 电路板 | 高速铜连接 | 4.06% | 3.26% | 3.01% | 3.01% | | 消费电子代工 | 英伟达产业链 | HBM | Al手机 | 2.11% | 2.6 ...

近日该股表现 | 日期 | 当日涨跌幅（%） | 换手率（%） | 主力资金净流入（万元） | | --- | --- | --- | --- | | 2025.07.07 | 0.79 | 8.91 | -2188.80 | | 2025.07.04 | 9.97 | 3.08 | 2280.71 | | 2025.07.03 | 10.02 | 1.63 | 3363.95 | | 2025.07.02 | 0.10 | 1.04 | 221.73 | | 2025.07.01 | 3.36 | 1.25 | -38.41 | | 2025.06.30 | 0.60 | 1.31 | -1014.58 | | 2025.06.27 | -0.20 | 0.95 | -338.62 | | 2025.06.26 | -1.66 | 0.62 | 78.42 | | 2025.06.25 | -0.87 | 0.74 | 64.62 | | 2025.06.24 | 2.58 | 0.98 | -394.28 | （文章来源：证券时报网） 卫信康再度涨停，4个交易日内录得3个涨停，累计涨幅为34.16%，累计 ...

New Stock Issuance - Huadian New Energy (证券代码: 730930) issued shares at a price of 3.18 on July 7, 2025[1] - Jichuan Pharmaceutical (证券代码: 600566) has a tender offer period from June 18 to July 17, 2025[1] - ST Yazhen (证券代码: 603389) has a tender offer period from June 10 to July 9, 2025[1] Trading Alerts - The last trading day for TSM Jinguang (证券代码: 600190) is in 9 trading days[1] - The last trading day for TSM Jinyou (证券代码: 600462) is in 5 trading days[1] - The last trading day for TSM Gongzhi (证券代码: 000584) is in 3 trading days[1] Abnormal Fluctuations - Northern Long (证券代码: 301357) is experiencing severe abnormal fluctuations[1] - ST Dongjing (证券代码: 002199) reported abnormal fluctuations[3] - ST Yunchuang (证券代码: 835305) reported abnormal fluctuations on July 4, 2025[3]

证券代码：603676 证券简称：卫信康 公告编号：2025-044 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 西藏卫信康医药股份有限公司（以下简称"公司"）股票连续 2 个交易日 （2025 年 7 月 3 日、7 月 4 日）日收盘价格涨幅偏离值累计超过 20%，根据《上 海证券交易所交易规则》的有关规定，属于股票交易异常波动情形。 经公司自查，并向公司实际控制人、控股股东及其一致行动人核实，截 至本公告披露日，确认不存在应披露而未披露的重大事项。 公司股票交易连续 2 个交易日（2025 年 7 月 3 日、7 月 4 日）日收盘价格涨 幅偏离值累计超过 20%，属于《上海证券交易所交易规则》规定的股票交易异常 波动情形。 二、公司关注并核实的相关情况 西藏卫信康医药股份有限公司 目前公司基本面未发生重大变化，敬请广大投资者注意二级市场交易风 险，理性决策，审慎投资。 一、股票交易异常波动的具体情况 经公司自查，未发现对公司股票交易价格可能产生重大影响的媒体报道或市 场传闻，亦 ...

Group 1 - TaiLong Pharmaceutical plans to apply for the registration and issuance of super short-term financing bonds not exceeding 800 million yuan, with a maturity of no more than 270 days, for purposes including replacing bank loans and supplementing working capital [1] - GuoXin Technology won a bid for a 46 million yuan automotive airbag ignition driver chip project, indicating its growing presence in the automotive semiconductor market [1] - GuoMai Technology expects a net profit increase of 60.52% to 100.33% for the first half of 2025, with a projected net profit of 125 million to 156 million yuan [2] Group 2 - ChangAluminum's subsidiary signed a 165 million yuan contract for the customized construction of a clinical and industrial base for a vaccine project, highlighting its involvement in the biopharmaceutical sector [3] - ZhongSalt Chemical acquired exploration rights for natural soda ash in Inner Mongolia for 929,000 yuan, expanding its resource base [4] - Six Kingdom Chemical announced the resignation of its deputy general manager, which may impact its operational strategy [5][6] Group 3 - FuYuan Pharmaceutical received a drug registration certificate for Bisoprolol Amlodipine tablets, indicating its expansion in the hypertension treatment market [7][8] - GuanShi Technology's subsidiary received a government subsidy of 7 million yuan, which is 45.29% of its net profit for the previous year, enhancing its financial position [9] - XiZhong Technology plans to repurchase shares worth between 75 million and 150 million yuan, aimed at employee stock ownership plans or equity incentives [10] Group 4 - BeiLu Pharmaceutical's subsidiary received approval for the raw material drug Iopromide, which is used as a contrast agent for various imaging examinations [12] - HongHui New Materials obtained a patent for a water-based protective paint for hardware parts, enhancing its product portfolio [13] - BoJi Pharmaceutical's subsidiary received two patents related to high bioavailability formulations, indicating innovation in biopharmaceutical technology [14] Group 5 - ChengJian Development received a cash dividend of 23.625 million yuan from its investment in Huaneng Capital, contributing to its investment income [15] - JiuZhou Pharmaceutical's subsidiary received a drug registration certificate for Sildenafil Citrate orally disintegrating tablets, expanding its product offerings in the erectile dysfunction treatment market [16] - RuiAng Gene's subsidiary received a government subsidy of 176,290 yuan, supporting its operational activities [17] Group 6 - FengFan Technology plans to acquire 100% equity of a subsidiary for 48 million yuan, indicating strategic expansion in the renewable energy sector [18] - AoJing Medical's subsidiary received a medical device production license, allowing it to manufacture absorbable surgical dressings [19] - TaiLin Bio's subsidiary won land use rights for an industrial site, facilitating its high-performance filter project [20] Group 7 - KaiPu Bio received a patent for a method and device for analyzing genomic copy number variations, enhancing its capabilities in molecular diagnostics [21] - Shanghai KaiBao received a drug registration certificate for Phlegm-Heat Clearing Capsules, which can be used in the treatment of COVID-19 symptoms [23] - TuoJing Life received two patents for high uniformity streptavidin applications, improving its diagnostic product stability [25] Group 8 - AnKe Bio's AK2024 injection received approval for clinical trials, marking a significant advancement in cancer treatment [26] - HuanYuan Pharmaceutical expects a net profit of 142 million to 160 million yuan for the first half of 2025, reflecting substantial growth [27] - JinHongShun terminated a major asset restructuring plan due to a lack of consensus among parties involved, impacting its strategic direction [28] Group 9 - HeZhan Energy signed a 177 million yuan contract for the sale of steel-concrete tower structures, indicating strong demand in the renewable energy sector [29] - InSai Group's acquisition plan for an 80% stake in ZhiZheTongXing was accepted by the Shenzhen Stock Exchange, indicating growth in its consulting business [30] - JiuDian Pharmaceutical received a drug registration certificate for Zinc Granules, enhancing its product line in gastrointestinal treatments [32] Group 10 - GuoYao Modern plans to publicly transfer a 51% stake in its subsidiary to optimize resource allocation [34] - GuoYao Modern's subsidiary received a drug registration certificate for Perindopril Indapamide tablets, expanding its hypertension treatment portfolio [36] - ZhongGong International signed a 175 million yuan engineering consulting service contract, showcasing its capabilities in project management [38] Group 11 - China Railway won contracts worth approximately 5.343 billion yuan for overseas construction projects, indicating its strong international presence [39] - JunPu Intelligent signed a framework contract for humanoid robot sales worth about 28.25 million yuan, reflecting growth in the robotics sector [41] - Sinopec's chairman resigned due to age, which may lead to changes in corporate governance [42] Group 12 - JiuFeng Energy's controlling shareholder plans to reduce their stake by up to 0.71%, indicating potential changes in ownership structure [44] - Zhejiang Oriental's subsidiary plans to establish a 1.74 billion yuan equity investment fund, focusing on strategic emerging industries [46] - ChenGuang New Materials received a government subsidy of 26 million yuan, significantly impacting its financial performance [48]

关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、获得补助的基本情况 2025 年 3 月 27 日、6 月 30 日，西藏卫信康医药股份有限公司（以下简称"公 司"）及全资子公司西藏中卫诚康药业有限公司收到 2024 年企业发展金合计 3,434.37 万元，该笔政府补助与收益相关，占公司 2024 年度经审计归属于上市 公司股东净利润的 13.95%。 二、补助的类型及其对公司的影响 证券代码：603676 证券简称：卫信康 公告编号：2025-043 西藏卫信康医药股份有限公司 2025 年 7 月 1 日 公司将按照《企业会计准则第 16 号——政府补助》相关规定，将上述与收 益相关的政府补助 3,434.37 万元列入其他收益。上述政府补助的取得，将对公 司 2025 年度的净利润产生一定影响。具体的会计处理及其对公司相关财务数据 的影响将以会计师事务所年度审计确认后的结果为准。敬请广大投资者注意投资 风险。 西藏卫信康医药股份有限公司董事会 特此公告。 ...

证券代码：603676 证券简称：卫信康 公告编号：2025-042 西藏卫信康医药股份有限公司 关于公司合作产品通过仿制药质量和疗效一致性评价的公告 申请类型：补充申请 受理号：CYHB2350909 药品注册标准编号：YBH15202025 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，西藏卫信康医药股份有限公司（以下简称"公司"）合作生产方山西普德药 业有限公司（以下简称"普德药业"）收到国家药品监督管理局（以下简称"国家药监 局"）核准签发的注射用多种维生素（12）《药品补充申请批准通知书》，该药品通过仿 制药质量和疗效一致性评价。注射用多种维生素（12）系由公司自主研发、普德药业负 责药品注册、生产，为公司核心产品。现就相关事项公告如下： 一、药物基本情况 药物名称：注射用多种维生素(12) 剂型：注射剂 注册分类：化学药品 规格：5ml/支 原药品批准文号：国药准字 H20093720 上市许可持有人：山西普德药业有限公司 药品生产企业：山西普德药业有限公司 审批结论：根据《中华人民共和国药品管理法》、《国 ...